<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841150</url>
  </required_header>
  <id_info>
    <org_study_id>CR108171</org_study_id>
    <secondary_id>54179060CLL1021</secondary_id>
    <nct_id>NCT02841150</nct_id>
  </id_info>
  <brief_title>Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 560-mg Tablet Compared to the Four IMBRUVICA 140 mg Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of
      ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ibrutinib</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration (tmax) of Ibrutinib</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last]) of Ibrutinib</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Ibrutinib</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (Lambda[z]) of Ibrutinib</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t[1/2]) of Ibrutinib</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of IMBRUVICA</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration (tmax) of IMBRUVICA</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last]) of IMBRUVICA</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of IMBRUVICA</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (Lambda[z]) of IMBRUVICA</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t[1/2]) of IMBRUVICA</measure>
    <time_frame>Day 1 (Pre-dose) up to Day 3</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events as a measure of safety and tolerability</measure>
    <time_frame>Baseline up to 14 days after last dose of study drug (Day 17)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMBRUVICA (Treatment A)</intervention_name>
    <description>IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <other_name>Ibrutinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib (Treatment B)</intervention_name>
    <description>Ibrutinib (test treatment), 1*560 mg, tablet.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed an informed consent form (ICF) indicating that he or she understands the
             purpose of and procedures required for the study and is willing to participate in the
             study, before any study related procedures take place

          -  Willing and able to adhere to the prohibitions and restrictions specified in the
             protocol

          -  If a woman, must be of non-childbearing potential, defined as either: a)
             Postmenopausal: A postmenopausal state is defined as no menses for at least 12 months
             without an alternative medical cause and a serum follicle stimulating hormone (FSH)
             level in the postmenopausal range (greater than [&gt;]40 international units per liter
             [IU/L] or milliinternational units per milliliter [mIU/mL]). b) Permanently sterile:
             Permanent sterilization methods include hysterectomy, bilateral salpingectomy,
             bilateral tubal occlusion/ligation procedures (without reversal operation), bilateral
             oophorectomy, and/or transcervical sterilization

          -  If a woman, must have a negative serum beta-human chorionic gonadotropin (beta-hCG)
             pregnancy test at screening and on Day -1 of each treatment period

          -  Non-smoker for at least 2 months prior to screening

        Exclusion Criteria:

          -  Use of any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for acetaminophen/paracetamol, topical therapies, and hormone
             replacement therapy within 14 days before the first dose of the study drug is
             scheduled

          -  History of clinically significant allergies, especially known hypersensitivity or
             intolerance to sulfonamide or beta-lactam antibiotics

          -  Known allergy to the study drug or any of the excipients of the formulation

          -  Unable to swallow solid, oral dosage forms whole with the aid of water (participants
             may not chew, divide, dissolve, or crush the study drug)

          -  Positive test for human immunodeficiency virus type 1 (HIV-1) or HIV-2 antibodies at
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

